Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2014, vol. 23, nr 5, September-October, p. 705–713

Publication type: original article

Language: English

Effects of a Tumor Necrosis Factor-Alpha Inhibitor (Etanercept) on the Sciatic Nerve in a Hypoxic Ischemia-Induced Neonatal Rat Model

Belgin Buyukakilli1,A,B,C,D,E,F, Aytug Atici2,A,B, Ebru Balli3,C,D, Aziz Ozkan2,A,B, Serkan Gurgul4,B,C, Bahar Tasdelen5,C,D, Oykut Dagtekin3,C

1 Department of Biophysics, Medical Faculty, Mersin University, Mersin, Turkey

2 Department of Pediatrics, Division of Neonatology, Medical Faculty, Mersin University, Mersin, Turkey

3 Department of Histology and Embryology, Medical Faculty, Mersin University, Mersin, Turkey

4 Department of Biophysics, Medical Faculty, Gaziosmanpasa University, Tokat, Turkey

5 Department of Biostatistics, Medical Faculty, Mersin University, Mersin, Turkey

Abstract

Background. Neonatal hypoxic-ischemic (HI) injury has been considered to have acute and long term deleterious effects on many tissues, including the peripheral nerve.
Objectives. In this study, the effects of a tumor necrosis factor-alpha (TNF-α) inhibitor (etanercept) on peripheral nerve damage and the ultrastructure of the sciatic nerve and gastrocnemius muscle in rats exposed to HI during the neonatal period were examined.
Material and Methods. In this study, 45 seven-day-old rats were used and they were divided into three groups. The right carotid arteries of the rats in the saline and etanercept groups were ligated and put in a hypoxia chamber containing 8% oxygen for two hours. Just after hypoxia, the etanercept group was given 10 mg/kg etanercept, but the saline group had only saline intraperitoneally. The sham group rats’ carotid arteries were not ligated or put in hypoxia. The amplitude, area and latency of sciatic nerve compound motor action potential (CMAP), which mainly reflects axonopathy and myelinopathy, were measured using standard techniques in the seventeenth week following the HI. Sciatic nerve and gastrocnemius muscle were evaluated with a transmission electron microscope, and grading for myelin sheath damage was done to all groups.
Results. Neuropathy was seen in rats after HI. While treatment with etanercept showed a protective effect for the axons of sciatic nerve, demyelination could not be recovered with etanercept.
Conclusion. This study is the first in literature to show a partial interruption of the signal through the peripheral nerve fibers caused by axonal and myelin dysfunction continuation in rats exposed to HI after birth, in the 17th week.

Key words

action potentials, etanercept, peripheral nerves, neonatal ischemia, neonatal hypoxia.

References (35)

  1. Buyukakilli B, Atıcı A, Büyükdereli Z, Taşdelen B, Güneş S, Turhan AH: Protective effects of platelet-activating factor antagonist ABT-491 on the peripheral nerves in hypoxic ischemia-induced neonatal rat model. Turkiye Klinikleri J Med Sci 2011, 31, 1179–1185.
  2. Buyukakilli B, Atici A, Özkan A, Balli E, Güneş S, Turhan AH, Hallioglu O, Kanik A: The effect of tumor necrosis factor-α inhibitor soon after hypoxia-ischemia on heart in neonatal rats. Life Sci 2012, 90, 838–845.
  3. Hendriksen PH, Oey PL, van Veen BK, Wallinga-de Jonge W, Veldman H: Muscle conduction velocity and morphology after prolonged hypoxemia and diabetes in rats. Electromyogr Clin Neurophysiol 1992, 32, 491–497.
  4. Nukada H, van Rij AM, Packer SG, McMorran PD: Pathology of acute and chronic ischaemic neuropathy in atherosclerotic peripheral vascular disease. Brain 1996, 119, 1449–1460.
  5. Nukada H, McMorran PD: Perivascular demyelination and intramyelinic oedema in reperfusion nerve injury. J Anat 1994, 185, 259–266.
  6. Ress AM, Babovic S, Angel MF, Im MJ, Dellon AL, Manson PN: Free radical damage in acute nerve compression. Ann Plas Surg 1995, 34, 388–395.
  7. Schmelzer JD, Zochodne DW, Low PA: Ischemic and reperfusion injury of rat peripheral nerve. Proc Nat Acad Sci USA 1989, 86, 1639–1642.
  8. Clark SM, Basraon SK, Hankins GDV: Intrapartum Asphyxia, Neonatal Encephalopathy, Cerebral Palsy, and Obstetric Interventions in the Term and Near-Term Infant. NeoReviews 2013, 14, 13–21.
  9. Villapol S, Gelot A, Renolleau S, Charriaut-Marlangue C: Astrocyte Responses after Neonatal Ischemia: The Yin and the Yang. Neuroscientist 2008, 14, 339–344.
  10. Wagner R, Myers RR: Schwann cells produce tumor necrosis factor alpha: expression in injured and non-injured nerves. Neuroscience 1996, 73, 625–629.
  11. Kato K, Liu H, Kikuchi S, Myers RR, Shubayev VI: Immediate anti-tumor necrosis factor-a (etanercept) therapy enhances axonal regeneration after sciatic nerve crush. J Neurosci Res 2010, 88, 360–368.
  12. Li F, Fang L, Huang S, Yang Z, Nandi J, Thomas S, Chen C, Camporesi E: Hyperbaric oxygenation therapy alleviates chronic constrictive injury-induced neuropathic pain and reduces tumor necrosis factor-alpha production. Anesth Analg 2011, 113, 626–633.
  13. Liou JT, Liu FC, Mao CC, Lai YS, Day YJ: Inflammation confers dual effects on nociceptive processing in chronic neuropathic pain model. Anesthesiology 2011, 114, 660–672.
  14. Mulleman D, Mammou S, Griffoul I, Watier H, Goupille P: Pathophysiology of disk-related sciatica. I. Evidence supporting a chemical component. Joint Bone Spine 2006, 73, 151–158.
  15. Olmarker K, Rydevik B: Selective inhibition of tumor necrosis factor-alpha prevents nucleus pulposus-induced thrombus formation, intraneural edema, and reduction of nerve conduction velocity. Possible implications for future pharmacologic treatment strategies of sciatica. Spine (Phila Pa 1976) 2001, 26, 863–869.
  16. Burtrum D, Silverstein FS: Hypoxic–ischemic injury stimulates glial fibrillary acidic protein mRNA and protein expression in neonatal rats. Exp Neurol 1994, 126, 112–118.
  17. Towfighi J, Mauger D: Temporal evolution of neuronal changes in cerebral hypoxia-ischemia in developing rats: a quantitative light microscopic study. Dev Brain Res 1998, 109, 169–177.
  18. Vannucci RC, Towfighi J, Vannucci SJ: Hypoxic preconditioning and hypoxic-ischemic brain damage in the immature rat: pathologic and metabolic correlates. J Neurochem 1998, 71, 1215–1220.
  19. Balduini W, Angelis VD, Mazzoni E, Cimino M: Long-lasting behavioral alterations following a hypoxic/ischemic brain injury in neonatal rats. Brain Res 2000, 859, 318–325.
  20. Spandou E, Papadopoulou Z, Soubasi V, Karkavelas G, Simeonidou C, Pazaiti A, Guiba-Tziampiri O: Erythropoietin prevents long-term sensorimotor deficits and brain injury following neonatal hypoxia–ischemia in rats. Brain Res 2005, 1045, 22–30.
  21. Clancy B, Darlington RB, Finlay BL: Translating developmental time across mammalian species. Neuroscience 2001, 105, 7–17.
  22. Rice JE 3rd, Vannucci RC, Brierley JB: The influence of immaturity on hypoxic-ischemic brain damage in the rat. Ann Neurol 1981, 9, 131–141.
  23. Aminoff MJ: Electromyography in Clinical Practice. Churchill Livingstone, New York 1998.
  24. Kaptanoglu E, Palaoglu S, Surucu HS, Hayran M, Beskonakli E: Ultrastructural scoring of graded acute spinal cord injury in the rat. J Neurosurg 2002, 97, 49–56.
  25. Stirling DP, Stys PK: Mechanisms of axonal injury: internodal nanocomplexes and calcium deregulation. Trends Mol Med 2010, 16, 160–170.
  26. Nikolaeva MA, Mukherjee B, Stys PK: Na+-dependent sources of intra-axonal Ca2+ release in rat optic nerve during in vitro chemical ischemia. J Neurosci 2005, 25, 9960–9967.
  27. LoPachin RM, Lehning EJ: Mechanism of calcium entry during axon injury and degeneration. Toxicol App Pharmacol 1997, 143, 233–244.
  28. Ten VS, Bradley-Moore M, Gingrich JA, Stark RI, Pinsky DJ: Brain injury and neurofunctional deficit in neonatal mice with hypoxic-ischemic encephalopathy. Behav Brain Res 2003, 145, 209–219.
  29. Brambilla R, Ashbaugh JJ, Magliozzi R, Dellarole A, Karmally S, Szymkowski DE, Bethea JR: Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. Brain J Neurol 2011, 134, 736–2754.
  30. Murdoch C, Muthana M, Lewis CE: Hypoxia regulates macrophage functions in inflammation. J Immunol 2005, 175, 6257–6263.
  31. Nathan C: Immunology: Oxygen and the inflammatory cell. Nature 2003, 422, 675–676.
  32. Lahat N, Rahat MA, Kinarty A, Weiss-Cerem L, Pinchevski S, Bitterman H: Hypoxia enhances lysosomal TNF-α degradation in mouse peritoneal macrophages. Am J Physiol Cell Physiol 2008, 295, 2–12.
  33. Hempel SL, Monick MM, Hunninghake GW: Effect of hypoxia on release of IL-1 and TNF by human alveolar macrophages. Am J Respir Cell Mol Biol 1996, 14, 170–176.
  34. Frisén J: Determinants of axonal regeneration. Histol Histopathol1997, 12, 857–868.
  35. Fawcett JW, Keynes RJ: Peripheral nerve regeneration. Annu Rev Neurosci 1990, 13, 43–60.
© Wroclaw Medical University